Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization

Mark Gormley, BDS* [1,2], Tom Dudding, PhD[2], Steven J Thomas, PhD[2], Jessica Tyrrell, PhD[3],

Andrew R Ness, PhD[4], Miranda Pring, PhD[2], Danny Legge, PhD[5], George Davey Smith, FRS[1],

Rebecca C Richmond, PhD[1], Emma E Vincent, PhD[1,5§], Caroline Bull, PhD[1,5§]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[4] University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, UK

[5] Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

§ Joint senior authors

* Corresponding author: mark.gormley@bristol.ac.uk

Abstract

A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors. Given the significant decline in smoking rates, particularly within developing countries, other potentially modifiable risk factors for head and neck cancer warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes and hypertension have been associated with head and neck cancer risk in multiple observational studies. However, obesity has also been correlated with smoking, with bias, confounding or reverse causality possibly explaining these findings. To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted (IVW) method) using genetic variants which were robustly associated with obesity, T2D and hypertension in genome-wide association studies (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and oropharyngeal cases, with 6,585 controls. We found limited evidence of a causal effect of genetically proxied body mass index (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on oral and oropharyngeal cancer risk. Similarly, there was limited evidence for related traits including type 2 diabetes and hypertension. Smoking appears to act as a mediator in the relationship between obesity and head and neck cancer.

Introduction

Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity and oropharynx is the 7th most common cancer, accounting for more than 660,000 new cases and 325,000 deaths annually worldwide (Johnson et al., 2020; Sung et al., 2021). Established risks include tobacco use, alcohol consumption (Hashibe et al., 2009) and human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and thought to be sexually transmitted (Gillison, Chaturvedi, Anderson, & Fakhry, 2015). A recent World Health Organization (WHO) report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors (World Health Organization (WHO), 2022). Smoking behaviour is declining, particularly in developing countries and it has been projected that obesity could even supersede smoking as the primary driver of cancer in the coming decades (World Health Organization (WHO), 2022). Despite changes in smoking rates, the incidence of HNC continues to rise and a changing aetiology has been proposed (Conway, 2018; Thomas, Penfold, Waylen, & Ness, 2018). Therefore, less established risks such as obesity and its related metabolic traits warrant investigation in HNC. However, obesity has been correlated with other HNC risk factors such as smoking (Carreras-Torres et al., 2018), alcohol (Alice R. Carter et al., 2019) and educational attainment (A. R. Carter et al., 2019), meaning independent effects are difficult to establish.

Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric and oesophageal (Centers for Disease Control and Prevention, 2021), but the effect on HNC risk remains unclear (World Health Organization

(WHO), 2022). Public health strategies have been unsuccessful in addressing the current

obesity epidemic at the population level, which could result in more cancer cases in the

years to come (Davey, 2004). Obesity and related metabolic traits such as type 2 diabetes

(T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer

in multiple observational studies. In the largest pooled analysis, obesity defined by higher

body mass index (BMI) was associated with a protective effect for HNC in current smokers

(hazard ratio (HR) 0.76, 95% confidence intervals (95%CI) 0.71–0.82, p <0.0001, per

5 kg/m^2) and conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per

5 kg/m^2, $p < 0.001$) (Gaudet et al., 2015). In the same study, a greater waist circumference

(WC) (HR 1.04, 95%CI 1.03–1.05 per 5 cm, $p < 0.001$) and waist-to-hip ratio (WHR)

(HR 1.07, 95%CI 1.05–1.09 per 0.1 unit, $p < 0.001$) were associated with increased HNC risk,

which did not vary by smoking status (Gaudet et al., 2015). However, more recent cohort

studies have failed to show a clear association between BMI and HNC (Cao et al., 2020; Diaz

et al., 2021; Gribsholt et al., 2020; Jiang et al., 2021; Ward et al., 2017). A meta-analysis of

observational studies investigating T2D with oral and oropharyngeal subsites, showed an

increased risk ratio (RR) of 1.15, 95%CI 1.02–1.29, P $heterogeneity$ = 0.277 (Gong, Wei, Yu, &

Pan, 2015), a result which is consistent with more recent independent cohorts (Jiang et al.,

2021; H.-B. Kim, Kim, Han, & Joo, 2021; S.-Y. Kim, Han, & Joo, 2019; Saarela et al., 2019).

Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or diastolic blood

pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer risk across

multiple studies (Christakoudi et al., 2020; H.-B. Kim et al., 2021; S.-Y. Kim et al., 2019; Seo,

Kim, Park, Han, & Joo, 2020; Stocks et al., 2012). Nonetheless, selection bias, confounding,

or reverse causation may explain the findings from these studies.

Mendelian randomization (MR) is an analytical approach which attempts to overcome the

challenges of conventional epidemiological studies. The method uses germline genetic

single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and

fixed at conception), to estimate the causal effects of exposures on disease outcomes

(Davey Smith & Hemani, 2014; Sanderson et al., 2022; Smith & Ebrahim, 2003). Using MR,

we recently found limited evidence for a role of circulating lipid traits in oral and

oropharyngeal cancer risk (Gormley et al., 2021), however other metabolic traits remain

untested in an MR framework. Here, we employ a two-sample MR approach, integrating

summary-level genetic data from the largest available GWAS for metabolic traits, including

obesity measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA_{1c}),

fasting glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their

causal effect on oral and oropharyngeal cancer risk. Given the potential correlation of

metabolic traits and established HNC risk factors, further evaluation of instrument-risk

factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour),

and educational attainment was carried out using MR.

Methods

Two-sample MR was performed using published summary-level data from the largest

available GWAS for each metabolic trait. MR makes three key assumptions, as described in

Fig. 1 (Davey Smith & Hemani, 2014; Smith & Ebrahim, 2003).

Figure 1. Directed acyclic graph (DAG) depicting Mendelian randomization applied to this

study

Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait

e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made

between X and Y if the following conditions are upheld:

(1) G is a valid instrument, reliably associated with X ('relevance');

(2) no measured (C) or unmeasured (U) confounding of the association between G and the Y

('exchangeability');

(3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

Exposure summary statistics for metabolic traits

To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with

traits of interest identified by previously conducted GWAS (**Supplementary Data 1**).

Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each

instrument were independent (linkage disequilibrium $R^2 < 0.001$). Following clumping,

genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of

806,834 individuals of European ancestry, including the Genetic Investigation

of ANthropometric Traits (GIANT) consortium and UK Biobank (Pulit et al., 2019); 45 SNPs

for WC, extracted from the same GWAS (Pulit et al., 2019); 209 SNPs for WHR extracted

from a GWAS meta-analysis describing 224,459 individuals of mainly European ancestry

(Shungin et al., 2015); 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of

Trans-Ethnic association studies) consortium of 228,499 cases and 1,178,783 controls

(Vujkovic et al., 2020); 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published

by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N =

151,188 and 105,056 individuals, respectively) (Lagou et al., 2021); 58 SNPs for HbA_{1c}, taken

from a meta-analyses of 159,940 individuals from 82 cohorts of European, African, East

Asian, and South Asian ancestry (Wheeler et al., 2017); Finally, 105 and 78 SNPs for SBP and DBP,

respectively, were extracted from a GWAS meta-analysis of over 1 million participants in UK

Biobank and the International Consortium of Blood Pressure Genome Wide Association

Studies (ICBP) (Evangelou et al., 2018) (**Supplementary Data 1**).

Outcome summary statistics for oral and oropharyngeal cancer

We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by

extracting exposure SNPs (**Supplementary Data 1**) from the largest available GWAS

performed on 6,034 cases and 6,585 controls from 12 studies which were part of the

Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (Lesseur et al.,

2016). Full details of the included studies, as well as the genotyping and imputation

performed, have been described previously (Dudding et al., 2018; Lesseur et al., 2016). In

brief, the study population included participants from Europe (45.3%), North America

(43.9%) and South America (10.8%). Cancer cases comprised the following the International

Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,

C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),

overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code

(other). A total of 954 individuals with cancers of hypopharynx, unknown code or

overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was

genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray,

custom designed for cancer studies by the OncoArray Consortium (Consortium, 2013).

Principle components analysis was performed using approximately 10,000 common markers

in low LD (r^2 < 0.004), minor allele frequency (MAF) > 0.05 and 139 population outliers were

removed.

Given the differential association of potential risk factors at each subsite (i.e. smoking,

alcohol and HPV infection)(Thomas et al., 2018), we performed stratified MR analyses for

oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we

used GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the

6,585 common controls in the GAME-ON GWAS (Lesseur et al., 2016).

Statistical analysis

Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by

integrating SNP associations for each metabolic trait (exposure, sample 1) with those for

oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic

variants reaching GWAS significance (p <5×10^{-8}). The nearest gene was identified using

SNPsnap and a distance of +/- 500 kb (Pers, Timshel, & Hirschhorn, 2014). Firstly, metabolic

trait-associated SNPs were extracted from oral and oropharyngeal cancer summary

statistics. Exposure and outcome summary statistics were harmonised using the

"*harmonise_data*" function of the TwoSampleMR package so that variant effect estimates

corresponded to the same allele. Palindromic SNPs were identified and corrected using

allele frequencies where possible (alleles were aligned when minor allele frequencies were <

0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effect-

estimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta)

(Wald, 1940). Multiple SNPs were then combined into multi-allelic instruments using

random-effects inverse-variance weighted (IVW) meta-analysis.

IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only

unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced

(Hemani, Bowden, & Smith, 2018). We therefore performed additional sensitivity analyses

to evaluate the potential for unbalanced horizontal pleiotropy using weighted median

(Bowden, Smith, Haycock, & Burgess, 2016), weighted mode (Hartwig, Smith, & Bowden,

2017) and MR-Egger (Bowden, Davey Smith, & Burgess, 2015) methods which are described

in detail elsewhere (Lawlor DA, 2019). In short, the weighted median stipulates that at least

50% of the weight in the analysis stems from valid instruments. Weighted mode returns an

unbiased estimate of the causal effect if the cluster with the largest weighted number of

SNPs for the weighted model are all valid instruments. Instruments are weighted by the

inverse variance of the SNP-outcome association.(Hartwig et al., 2017)

Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the

Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated (Bowden

et al., 2015). The InSIDE assumption states that the association between genetic instrument

and exposure should not be correlated with an independent path from instrument to the

outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated,

then the MR-Egger result may be biased (Lawlor DA, 2019). Gene variants must be valid

instruments and where there was evidence of violation of the negligible measurement error

(NOME) assumption (Bowden, Del Greco, et al., 2016), this was assessed using the I^2 statistic

and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias

adjustment (Bowden, Del Greco, et al., 2016). The variance of each trait explained by the

genetic instrument (R^2) was estimated and used to perform power calculations (Brion,

Shakhbazov, & Visscher, 2013). F-statistics were also generated. An F-statistic lower than 10

was interpreted as indicative of a weak instrument bias (Lawlor, Harbord, Sterne, Timpson,

& Davey Smith, 2008). To further assess the robustness of MR estimates, we examined

evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which

indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is

much larger than its degrees of freedom (No. of instrumental variables minus 1) (Bowden et

al., 2018). MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was

used to detect and correct for potential outliers (where Q-statistic $p < 0.05$) (Verbanck,

Chen, Neale, & Do, 2018).

Instrument-risk factor effects

Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer

risk in the primary MR analysis, we conducted further evaluation of the metabolic

instruments onto established HNC risk factors using two-sample MR. The largest available

GWAS were used for smoking initiation (a binary phenotype indicating whether an

individual had ever smoked in their life versus never smokers) (n=1,232,091) and alcoholic

drinks per week (defined as the average number of drinks per week aggregated across all

types of alcohol, n=941,280) from the GWAS and Sequencing Consortium of Alcohol and

Nicotine use (GSCAN) study (Liu et al., 2019). Summary statistics were also obtained from a

GWAS of general risk tolerance (n=939,908), derived from a meta-analysis of UK Biobank

(n=431,126) binary question *"Would you describe yourself as someone who takes risks?"*

and the 23andMe (n=508,782) question *"Overall, do you feel comfortable or uncomfortable*

taking risks?". The GWAS of risk tolerance was based on one's tendency or willingness to

take risks, making them more likely to engage in risk-taking behaviours more generally

(Karlsson Linner et al., 2019). A strong genetic correlation between sexual behaviours and

risk tolerance has been shown previously (Gormley et al., 2022). Finally, given the known

association between HNC and lower socioeconomic position, we used MR to examine

educational attainment (defined by years of schooling) (J. J. Lee et al., 2018). Outcome beta

estimates reflect the standard deviation of the phenotype.

Results

F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating

sufficient instrument strength for MR analyses (**Supplementary Table 1**). Genetic

instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective

metabolic trait (**Supplementary Table 1**). Based on the results of prior observational studies

we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits

on oral and oropharyngeal cancer. **Supplementary Fig. 1A-C** displays power estimates for

MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an

association with an OR of 1.2 or more at an α of 0.05 for combined oral and oropharyngeal

cancer. Power was lower for other metabolic traits and reduced when stratifying analyses

by subsite (**Supplementary Fig. 1**).

Estimated effect of adiposity on oral and oropharyngeal cancer risk

There was limited evidence of an effect of higher BMI or WHR on combined oral and

oropharyngeal cancer (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26, per 1 SD in BMI (4.81 kg/m^2)

and OR IVW 0.98, 95%CI 0.74–1.29, p = 0.88, per 1 SD in WHR (0.10 unit)) (**Table 1; Fig. 2;**

Supplementary Fig. 2 & 3). Results were consistent when analyses were stratified by subsite

(**Table 1**). WC, another measure of adiposity did show a protective direction of effect (OR

IVW 0.73, 95%CI 0.52–1.02, p = 0.07, per 1 SD increase in WC (0.09 unit)), particularly in the

oropharyngeal subsite (OR IVW 0.66, 95%CI 0.43–1.01, p = 0.06, per 1 SD increase in WC

(0.09 unit)) (**Table 1; Fig. 2; Supplementary Fig. 4**).

Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk

There was limited evidence for an effect of genetically-proxied T2D on combined oral and

oropharyngeal cancer (OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09, per 1-log unit higher odds of

T2D (**Table 1; Fig. 2; Supplementary Fig. 5**). Traits related to diabetes, including HbA$_{1c}$

resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR

IVW 0.56, 95%CI 0.32–1.00, p = 0.05, per 1-log-unit % higher HbA$_{1c}$), which remained only in

the oral subsite (OR IVW 0.48, 95%CI 0.24–0.93, p = 0.03, per 1-log-unit % higher HbA$_{1c}$)

following stratification (**Table 1; Fig. 2; Supplementary Fig. 6**). Conversely, there was limited

evidence of an effect for FG (OR IVW 1.06, 95%CI 0.68–1.66, p = 0.79, per 1-log unit increase

in mmol/L fasting glucose) (**Table 1; Fig. 2; Supplementary Fig. 7**) or FI (OR IVW 0.81, 95%CI

0.23–2.89, p = 0.75, per 1-log unit increase in mmol/L fasting insulin) on combined oral and

oropharyngeal cancer risk (**Table 1; Fig. 2; Supplementary Fig. 8**)

Estimated effect of increased blood pressure oral and oropharyngeal cancer risk

Finally, there was limited evidence for an effect of SBP on risk of combined oral and

oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in

systolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig. 9**), which did not change when

stratified by subsite. However, there was some weak evidence for a protective effect of DBP

on risk of combined oral and oropharyngeal cancer (OR IVW 0.93, 95%CI 0.87–1.00, p = 0.05,

per 1 unit mmHg increase in diastolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig.**

10).

 Table 1. Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
Exposure	Outcome	Exposure/ Outcome source	Outcome N	Number of SNPs	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
BMI	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS (Pulit et al., 2019)/ GAME-ON (Lesseur et al., 2016)	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer		2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
	Oropharyngeal cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
WC	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS (Pulit et al., 2019)/ GAME-ON (Lesseur et al., 2016)	6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
	Oral cancer		2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
WHR	Oral and oropharyngeal cancer combined	Shungin *et al.* GWAS (Shungin et al., 2015)/ GAME-ON (Lesseur et al., 2016)	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
	Oral cancer		2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer		2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
T2D	Oral and oropharyngeal cancer combined	Vujkovic *et al.* GWAS (Vujkovic et al., 2020)/ GAME-ON (Lesseur et al., 2016)	6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer		2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
	Oropharyngeal cancer		2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA$_{1c}$	Oral and oropharyngeal cancer combined	Wheeler *et al.* GWAS (Wheeler et al., 2017)/ GAME-ON	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07
	Oral cancer		2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06

	Oropharyngeal cancer	(Lesseur et al., 2016)	2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
FG	Oral and oropharyngeal cancer combined	Lagou *et al.* GWAS (Lagou et al., 2021)/ GAME-ON (Lesseur et al., 2016)	6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80
	Oral cancer		2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
FI	Oral and oropharyngeal cancer combined	Lagou *et al.* GWAS (Lagou et al., 2021)/ GAME-ON (Lesseur et al., 2016)	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21)	0.63
	Oropharyngeal cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
SBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS (Evangelou et al., 2018)/ GAME-ON (Lesseur et al., 2016)	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
	Oral cancer		2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
DBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS (Evangelou et al., 2018)/ GAME-ON (Lesseur et al., 2016)	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngeal cancer		2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

 Figure 2. Mendelian randomization results of genetically-proxied metabolic disorders with

risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON

Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist

circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin;

SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically

predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L

fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg

increase) and DBP (1 unit mmHg increase).

Sensitivity analyses

We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW

(**Table 1; Fig. 2**). The results of these analyses generally followed the same pattern as the

IVW results reported above, however, there were a number of exceptions. The results for

HbA1c were not robust to sensitivity testing (p > 0.05 across methods) (**Table 1; Fig. 2**). In

the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result

provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97,

p = 0.02). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI

0.72–0.99, *p* = 0.04). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the

weighted mode supported IVW result, providing evidence of a protective effect (OR

weighted mode 0.37, 95%CI 0.17–0.83, *p* = 0.02) (**Table 1; Fig. 2**).

There was clear evidence of heterogeneity in the SNP effect estimates for IVW and MR

Egger regression for WHR (Q IVW 213.04, *p* = 0.03; Q MR Egger 209.24, *p* = 0.04), T2D (Q

IVW 328.24, p < 0.01; Q MR Egger 328.21, *p* < 0.01), FI (Q IVW 32.87, *p* < 0.01; Q MR Egger

31.63, *p* < 0.01) and DBP (Q IVW 95.82 *p* < 0.01; Q MR Egger 95.22, *p* < 0.01)

(**Supplementary Table 2**). MR-Egger intercepts were not strongly indicative of directional

pleiotropy (**Supplementary Table 3**), but there were outliers present on visual inspection of

scatter plots (**Supplementary Figs. 11-19**). MR-PRESSO identified 19 outliers for BMI, 2

outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA_{1c}, 1 outlier for

FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (**Supplementary Tables 4-5**). When

correcting for these outliers, this yielded effects consistent with the primary IVW analysis

except for adiposity and T2D instruments, which demonstrated a protective effect on

combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW

0.77, 95%CI 0.62–0.94, *p* = 0.01, per 1 SD in BMI (4.81 kg/m^2)); WC (OR IVW 0.65, 95%CI

0.47–0.89, *p* = 0.01, per 1 SD in WC (0.09 unit)), and T2D (OR IVW 0.91, 0.84–0.99, *p* = 0.03,

per 1-log unit higher odds of T2D) (**Supplementary Table 6**). Where there was evidence of

violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I^2 statistic <0.90)

(**Supplementary Table 7**), MR-Egger was performed with SIMEX correction. SIMEX effects

were consistent with the null, except for SBP where an increased risk effect on combined

oral and oropharyngeal cancer was found (OR IVW 1.15, 95%CI 1.05–1.26, $p < 0.01$, per 1

unit mmHg increase in diastolic blood pressure) (**Supplementary Table 8**).

Evaluating instrument-risk factor effects

Where there was some evidence for an effect of BMI, WC, WHR , T2D , HbA_{1c} and DBP on

oral and oropharyngeal cancer, we carried out further MR analysis to determine causal

effects of these metabolic instruments on established risk HNC risk factors. Obesity-related

measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW

0.21 (standard error (SE) 0.03), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WC (Beta

IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18

(SE 0.03), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)) (**Supplementary Table 9**). There

was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption

of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), $p < 0.01$, per 1 SD increase in

BMI (4.81 kg/m2)), WC (Beta IVW -0.09 (SE 0.02), $p < 0.001$, per 1 SD increase in WC (0.09

unit)) and T2D (Beta IVW -0.02 (SE 0.01), $p < 0.001$, per 1-log unit higher odds of T2D). BMI

(Beta IVW 0.04 (SE 0.01), $p <0.001$, per 1 SD increase in BMI (4.81 kg/m2)) and WHR (Beta

IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also estimated to

increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D

were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -

0.16 (SE 0.02), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WHR (Beta IVW -0.11 (SE

0.02), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p

< 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both

heterogeneity (**Supplementary Table 10**) and genetic pleiotropy (**Supplementary Table 11**)

across most instrument-risk factor effects. With the exception of alcohol drinks per week,

the estimated instrument-risk factor effects remained unchanged following the removal of

outlier SNPs detected by MR-PRESSO (**Supplementary Table 12**).

Discussion

In this MR study we found limited evidence to support a causal role of genetically-predicted

metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been

previously overestimated in observational studies. Where weak evidence for an effect was

found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis,

including outlier correction. There was also strong evidence for instrument-risk factor

effects, suggesting smoking may be a mediator between obesity and HNC.

There are several biological mechanisms linking metabolic traits and cancer, but these have

not been well explored in HNC (Gatenby & Gillies, 2004; Grimberg, 2003; Tseng, Lin, Lin, &

Weng, 2014). Dysregulated metabolism is likely linked to the probability a cancer develops

and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic

demands of chronic cell proliferation via metabolic reprogramming, enhancing or

suppressing the activity of metabolic pathways relative to that in benign tissue (DeNicola &

Cantley, 2015). In the largest pooled analysis of 17 case-control studies, BMI was associated

with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the

larynx (HR 1.42, 95%CI 1.19–1.70 per 5 kg/m^2, p < 0.001) (Gaudet et al., 2015). Laryngeal

cancer was not included in our study given that GWAS summary data were not available for

this subsite and future analysis of this region is therefore warranted. BMI effects on both

the oral (HR 1.10, 95%CI 0.97–1.25, p = 0.14) and oropharyngeal cancer (HR 0.98, 95%CI

0.84–1.14, p = 0.77) subsites were consistent with the effects found in our study (oral

cancer OR 0.92, 95%CI 0.71–1.19, p = 0.53; oropharyngeal cancer OR 0.89, 0.68–1.15, p =

0.36) (Gaudet et al., 2015). Conversely, the same pooled analysis found an increased risk for

both WC (HR 1.09, 95%CI 1.03–1.16, p = 0.006) and WHR (HR 1.17, 95%CI 1.02–1.34, p =

0.02), mainly in the oral subsite which were not replicated in our MR analysis. Varying

patterns of results for these anthropometric measures have been found when stratifying by

smoking status within observational studies (Gaudet et al., 2015). The relationship between

obesity and HNC is complex. There appears to be a positive association between low BMI

(<18.5 kg/m^2) and HNC risk, and a protective effect of BMI on HNC risk in current smokers

but conversely, a higher risk in never smokers (Gaudet et al., 2015). This suggests smoking

is a confounder, both as an established risk factor for HNC and in its correlation with weight,

with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption

and appetite suppression (Williamson et al., 1991). Instrument-risk factor effect estimates

from this study suggest smoking is also a mediator, through which metabolic traits such as

BMI influence HNC risk.

Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride,

low HDL-C and insulin resistance) being strongly associated with common cancers such as

colorectal and breast (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012), this does not

appear to be the case in head and neck cancer. A recent prospective study of 474,929

participants from UK Biobank investigating the effect of metabolic syndrome suggested

those with the condition had no increased HNC risk (HR 1.05, 95%CI 0.90–1.22, p = 0.560)

(Jiang et al., 2021). No definitive causal effects were detected for individual components of

metabolic syndrome components either, supporting our MR results. While another large

meta-analysis found individuals with T2D have an elevated risk of oral cancer (Gong et al.,

2015), other more recent studies have found this effect to be mostly in laryngeal subsite (HR

1.25, 95%CI 1.12–1.40) which again we could not investigate in this study (H.-B. Kim et al.,

2021). Hypertension is the most consistently reported metabolic trait to have an

observational association with HNC risk across the subsites (Christakoudi et al., 2020; H.-B.

Kim et al., 2021; S.-Y. Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). We did not

identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again

suggesting the possibility of residual confounding in observational studies.

MR was employed in this study in an attempt to overcome the drawbacks of conventional

epidemiological studies. However, there are a number of limitations with using this

approach and if MR assumptions are violated, this too can generate spurious conclusions.

While there was no evidence of weak instrument bias (F statistics > 10), there was

heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is

expected to some extent, given that we are instrumenting multiple biological pathways that

contribute to complex metabolic phenotypes. The use of multiple related instruments for

each metabolic trait may, however, provide some additional confidence in the overall

findings. Given the low percentage of variation explained (R^2) for some instruments, as well

as the relatively small number of oral and oropharyngeal cancer cases, power to detect an

effect may have been an issue in some of our analyses.

As with observational studies, there may be issues of measurement error or

misclassification in genetic epidemiology, given BMI is simply a function of mass and height

and does not specifically measure adiposity. However, BMI has been shown to be an

acceptable proxy when used in large samples sizes, correlating with both total body fat

(Browning et al., 2011) and total abdominal adipose tissue (Ross, Léger, Morris, de Guise, &

Guardo, 1992), which is thought to present a greater health risk than fat deposited

elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR,

which may be better proxies of abdominal adiposity, compared to BMI (C. M. Lee, Huxley,

Wildman, & Woodward, 2008). SNPs used to proxy these metabolic traits, particularly

obesity-related measures BMI, WC and WHR were strongly associated with smoking. Given

the heterogeneity of these complex metabolic traits, future work could further examine

their pathway specific effects (Udler et al., 2018).

Conclusion

Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on

oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be

effective modifiable risk factors to prioritise as part of future prevention strategies in head

and neck cancer. The effect of metabolic traits on the risk of this disease may have been

overestimated in previous observational studies, but these cannot be directly compared

given the differences in methodological approaches and the interpretation of estimates.

Smoking appears to act as a mediator in the relationship between obesity and HNC.

Although there is no clear evidence that changing body mass will reduce of increase the risk

of HNC directly, dental and medical teams should be aware of the risk of smoking in those

who are overweight and therefore the greater risk of cancer when providing smoking

cessation and appropriate weight loss advice.

References

Bowden, J., Davey Smith, G., & Burgess, S. (2015): Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression.

International Journal of Epidemiology, 44, 512-525.

Bowden, J., Del Greco, M. F., Minelli, C., Smith, G. D., Sheehan, N. A., & Thompson, J. R.

(2016): Assessing the suitability of summary data for two-sample Mendelian

randomization analyses using MR-Egger regression: the role of the I-2 statistic.

International Journal of Epidemiology, 45, 1961-1974.

Bowden, J., Smith, G. D., Haycock, P. C., & Burgess, S. (2016): Consistent Estimation in

Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

Estimator. *Genetic Epidemiology, 40*, 304-314.

Bowden, J., Spiller, W., Del Greco, F., Sheehan, N., Thompson, J., Minelli, C., & Smith, G. D.

(2018): Improving the visualization, interpretation and analysis of two-sample

summary data Mendelian randomization via the Radial plot and Radial regression.

International Journal of Epidemiology, 47, 1264-1278.

Brion, M. J., Shakhbazov, K., & Visscher, P. M. (2013): Calculating statistical power in

Mendelian randomization studies. *International Journal of Epidemiology, 42*, 1497-

1501.

Browning, L. M., Mugridge, O., Dixon, A. K., Aitken, S. W., Prentice, A. M., & Jebb, S. A.

(2011): Measuring abdominal adipose tissue: comparison of simpler methods with

MRI. *Obesity facts, 4*, 9-15.

Cao, Z., Li, S., Xu, F., Yang, X., Wang, Y., Zheng, X., & Yang, H. (2020): Association of obesity

status and metabolic syndrome with site-specific cancers: a population-based cohort

study. *British Journal of Cancer, 123*, 1336-1344.

Carreras-Torres, R., Johansson, M., Haycock, P. C., Relton, C. L., Davey Smith, G., Brennan,

P., & Martin, R. M. (2018): Role of obesity in smoking behaviour: Mendelian

randomisation study in UK Biobank. *BMJ (Clinical research ed.), 361*, k1767-k1767.

Carter, A. R., Borges, M.-C., Benn, M., Tybjærg-Hansen, A., Davey Smith, G., Nordestgaard,

B. G., & Lawlor, D. A. (2019): Combined Association of Body Mass Index and Alcohol

Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A

Mendelian Randomization Study. *JAMA Network Open, 2*, e190305-e190305.

Carter, A. R., Gill, D., Davies, N. M., Taylor, A. E., Tillmann, T., Vaucher, J., . . . Dehghan, A.

(2019): Understanding the consequences of education inequality on cardiovascular

disease: mendelian randomisation study. *BMJ, 365*, l1855.

Centers for Disease Control and Prevention. (2021). Obesity and Cancer [Internet] [cited

2022 Jun 18]. Retrieved from

https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or

%20having%20obesity,the%20United%20States%20each%20year.

Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., . . .

Tsilidis, K. K. (2020): Blood pressure and risk of cancer in the European Prospective

Investigation into Cancer and Nutrition. *International Journal of Cancer, 146*, 2680-

2693.

Consortium, O. (2013): Consortium launches genotyping effort. *Cancer Discov, 3*, 1321-1322.

Conway, D. I., Purkayastha, M., Chestnutt, I. G. (2018): The changing epidemiology of oral

cancer: definitions, trends, and risk factors. *British Dental Journal, 225*, 867-873.

Davey, R. C. (2004): The obesity epidemic: too much food for thought? *British Journal of*

Sports Medicine, 38, 360-363.

Davey Smith, G., & Hemani, G. (2014): Mendelian randomization: genetic anchors for causal

inference in epidemiological studies. *Human Molecular Genetics, 23*, R89-98.

DeNicola, G. M., & Cantley, L. C. (2015): Cancer's Fuel Choice: New Flavors for a Picky Eater.

Mol Cell, 60, 514-523.

Diaz, Y., Duarte-Salles, T., Recalde, M., Freisling, H., Davila-Batista, V., Leitzmann, M., &

Romieu, I. (2021): Body mass index and waist circumference in relation to the risk of

26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC*

Medicine, 19, 10-10.

Dudding, T., Johansson, M., Thomas, S. J., Brennan, P., Martin, R. M., & Timpson, N. J.

(2018): Assessing the causal association between 25-hydroxyvitamin D and the risk

of oral and oropharyngeal cancer using Mendelian randomization. *International*

Journal of Cancer, 143, 1029-1036.

Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012): Metabolic syndrome

and risk of cancer: a systematic review and meta-analysis. *Diabetes Care, 35*, 2402-

2411.

Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., . . . the

Million Veteran, P. (2018): Genetic analysis of over 1 million people identifies 535

new loci associated with blood pressure traits. *Nature Genetics, 50*, 1412-1425.

Gatenby, R. A., & Gillies, R. J. (2004): Why do cancers have high aerobic glycolysis? *Nature*

Reviews Cancer, 4, 891-899.

Gaudet, M. M., Kitahara, C. M., Newton, C. C., Bernstein, L., Reynolds, P., Weiderpass, E., . . .

Gapstur, S. M. (2015): Anthropometry and head and neck cancer:a pooled analysis of

cohort data. *International Journal of Epidemiology, 44*, 673-681.

Gillison, M. L., Chaturvedi, A. K., Anderson, W. F., & Fakhry, C. (2015): Epidemiology of

Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin*

Oncol, 33, 3235-3242.

Gong, Y., Wei, B., Yu, L., & Pan, W. (2015): Type 2 diabetes mellitus and risk of oral cancer

and precancerous lesions: a meta-analysis of observational studies. *Oral Oncology,*

51, 332-340.

Gormley, M., Dudding, T., Kachuri, L., Burrows, K., Chong, A. H. W., Martin, R. M., . . .

Richmond, R. C. (2022): Investigating the effect of sexual behaviour on

oropharyngeal cancer risk: a methodological assessment of Mendelian

randomization. *BMC Medicine, 20*, 40.

Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S., . . .

Richmond, R. C. (2021): Using genetic variants to evaluate the causal effect of

cholesterol lowering on head and neck cancer risk: A Mendelian randomization

study. *PLOS Genetics, 17*, e1009525.

Gribsholt, S. B., Cronin-Fenton, D., Veres, K., Thomsen, R. W., Ording, A. G., Richelsen, B., &

Sorensen, H. T. (2020): Hospital-diagnosed overweight and obesity related to cancer

risk: a 40-year Danish cohort study. *Journal of Internal Medicine, 287*, 435-447.

Grimberg, A. (2003): Mechanisms by which IGF-I may promote cancer. *Cancer biology &*

therapy, 2, 630-635.

Hartwig, F. P., Smith, G. D., & Bowden, J. (2017): Robust inference in summary data

Mendelian randomization via the zero modal pleiotropy assumption. *International*

Journal of Epidemiology, 46, 1985-1998.

Hashibe, M., Brennan, P., Chuang, S. C., Boccia, S., Castellsague, X., Chen, C., . . . Boffetta, P.

(2009): Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck

Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology

Consortium. *Cancer Epidemiology Biomarkers & Prevention, 18*, 541-550.

Hemani, G., Bowden, J., & Smith, G. D. (2018): Evaluating the potential role of pleiotropy in

Mendelian randomization studies. *Human Molecular Genetics, 27*, R195-R208.

Jiang, H., Zhou, L., Jiang, K., Huang, X., He, Q., & Yuan, J. (2021): The effect of metabolic

syndrome on head and neck cancer incidence risk: a population-based prospective

cohort study. *Cancer & metabolism, 9*, 25-25.

Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R.

(2020): Head and neck squamous cell carcinoma. *Nature Reviews Disease Primers, 6*,

92.

Karlsson Linner, R., Biroli, P., Kong, E., Meddens, S. F. W., Wedow, R., Fontana, M. A., . . .

Beauchamp, J. P. (2019): Genome-wide association analyses of risk tolerance and

risky behaviors in over 1 million individuals identify hundreds of loci and shared

genetic influences. *Nature Genetics, 51*, 245-257.

Kim, H.-B., Kim, G.-J., Han, K.-d., & Joo, Y.-H. (2021): Changes in metabolic syndrome status

and risk of laryngeal cancer: A nationwide cohort study. *PLoS One, 16*, e0252872-

e0252872.

Kim, S.-Y., Han, K.-d., & Joo, Y.-H. (2019): Metabolic Syndrome and Incidence of Laryngeal

Cancer: A Nationwide Cohort Study. *Scientific Reports, 9*, 667.

Lagou, V., Mägi, R., Hottenga, J.-J., Grallert, H., Perry, J. R. B., Bouatia-Naji, N., . . . Insulin-

related traits, C. (2021): Sex-dimorphic genetic effects and novel loci for fasting

glucose and insulin variability. *Nature Communications, 12*, 24.

Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N., & Davey Smith, G. (2008):

Mendelian randomization: using genes as instruments for making causal inferences

in epidemiology. *Statistics in Medicine, 27*, 1133-1163.

Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . (2019): A

Mendelian Randomization dictionary: Useful definitions and descriptions for

undertaking, understanding and interpreting Mendelian Randomization studies.

Lee, C. M., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008): Indices of abdominal

obesity are better discriminators of cardiovascular risk factors than BMI: a meta-

analysis. *J Clin Epidemiol, 61*, 646-653.

Lee, J. J., Wedow, R., Okbay, A., Kong, E., Maghzian, O., Zacher, M., . . . Social Science

Genetic Association, C. (2018): Gene discovery and polygenic prediction from a

genome-wide association study of educational attainment in 1.1 million individuals.

Nature Genetics, 50, 1112-1121.

Lesseur, C., Diergaarde, B., Olshan, A. F., Wunsch, V., Ness, A. R., Liu, G., . . . Brennan, P.

(2016): Genome-wide association analyses identify new susceptibility loci for oral

cavity and pharyngeal cancer. *Nature Genetics, 48*, 1544-1550.

Liu, M. Z., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F., . . . Psychiat, H. A. I. (2019):

Association studies of up to 1.2 million individuals yield new insights into the genetic

etiology of tobacco and alcohol use. *Nature Genetics, 51*, 237.

Pers, T. H., Timshel, P., & Hirschhorn, J. N. (2014): SNPsnap: a Web-based tool for

identification and annotation of matched SNPs. *Bioinformatics, 31*, 418-420.

Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., . . .

Lindgren, C. M. (2019): Meta-analysis of genome-wide association studies for body

599   fat distribution in 694 649 individuals of European ancestry. *Human Molecular*

600   *Genetics, 28*, 166-174.

601 Ross, R., Léger, L., Morris, D., de Guise, J., & Guardo, R. (1992): Quantification of adipose

602   tissue by MRI: relationship with anthropometric variables. *J Appl Physiol (1985), 72*,

603   787-795.

604 Saarela, K., Tuomilehto, J., Sund, R., Keskimaki, I., Hartikainen, S., & Pukkala, E. (2019):

605   Cancer incidence among Finnish people with type 2 diabetes during 1989-2014.

606   *European Journal of Epidemiology, 34*, 259-265.

607 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R., . . .

608   Davey Smith, G. (2022): Mendelian randomization. *Nature Reviews Methods Primers,*

609   *2*, 6.

610 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d., & Joo, Y.-H. (2020): Hypertension is associated

611   with oral, laryngeal, and esophageal cancer: a nationwide population-based study.

612   *Scientific Reports, 10*, 10291.

613 Shungin, D., Winkler, T. W., Croteau-Chonka, D. C., Ferreira, T., Locke, A. E., Mägi, R., . . .

614   Mohlke, K. L. (2015): New genetic loci link adipose and insulin biology to body fat

615   distribution. *Nature, 518*, 187-196.

616 Smith, G. D., & Ebrahim, S. (2003): 'Mendelian randomization': can genetic epidemiology

617   contribute to understanding environmental determinants of disease? *International*

618   *Journal of Epidemiology, 32*, 1-22.

Stocks, T., Van Hemelrijck, M., Manjer, J., Bjorge, T., Ulmer, H., Hallmans, G., . . . Stattin, P.

(2012): Blood pressure and risk of cancer incidence and mortality in the Metabolic

Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979), **59***, 802-810.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F.

(2021): Global cancer statistics 2020: GLOBOCAN estimates of incidence and

mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*

Clinicians.

Thomas, S. J., Penfold, C. M., Waylen, A., & Ness, A. R. (2018): The changing aetiology of

head and neck squamous cell cancer: A tale of three cancers? *Clinical*

*Otolaryngology, **43***, 999-1003.

Tseng, K. S., Lin, C., Lin, Y. S., & Weng, S. F. (2014): Risk of head and neck cancer in patients

with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*

*Head Neck Surg, **140***, 746-753.

Udler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., . . . Florez, J.

C. (2018): Type 2 diabetes genetic loci informed by multi-trait associations point to

disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med, **15***,

e1002654.

Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018): Publisher Correction: Detection of

widespread horizontal pleiotropy in causal relationships inferred from Mendelian

randomization between complex traits and diseases. *Nature Genetics, **50***, 1196.

Vujkovic, M., Keaton, J. M., Lynch, J. A., Miller, D. R., Zhou, J., Tcheandjieu, C., . . . Program,

V. A. M. V. (2020): Discovery of 318 new risk loci for type 2 diabetes and related

vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.

Nature Genetics, 52, 680-691.

Wald, A. (1940): The Fitting of Straight Lines if Both Variables are Subject to Error. *The*

Annals of Mathematical Statistics, 11, 284-300, 217.

Ward, H. A., Wark, P. A., Muller, D. C., Steffen, A., Johansson, M., Norat, T., . . . Riboli, E.

(2017): Measured Adiposity in Relation to Head and Neck Cancer Risk in the

European Prospective Investigation into Cancer and Nutrition. *Cancer epidemiology,*

biomarkers & prevention : a publication of the American Association for Cancer

Research, cosponsored by the American Society of Preventive Oncology, 26, 895-904.

Wheeler, E., Leong, A., Liu, C. T., Hivert, M. F., Strawbridge, R. J., Podmore, C., . . . Meigs, J.

B. (2017): Impact of common genetic determinants of Hemoglobin A1c on type 2

diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-

wide meta-analysis. *PLoS Med, 14*, e1002383.

Williamson, D. F., Madans, J., Anda, R. F., Kleinman, J. C., Giovino, G. A., & Byers, T. (1991):

Smoking Cessation and Severity of Weight Gain in a National Cohort. *New England*

Journal of Medicine, 324, 739-745.

World Health Organization (WHO). (2022). WHO European Regional Obesity Report 2022.

[Internet] [cited 2022 Jun 06].

Ethics approval and consent to participate

All studies included as part of the GAME-ON network obtained approval and consent from

their respective institutions.

Consent for publication

Not applicable.

Availability of data and materials

Summary-level analysis was conducted using publicly available GWAS data as cited. Full

summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP

(OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August

2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-

bin/study.cgi?study_id=phs001202.v1.p1). There is one selected publication by Lesseur et

al. related to this data (Lesseur et al., 2016). Exposure data is publicly available from the

relevant studies and via the IEU Open GWAS (https://gwas.mrcieu.ac.uk/). MR analyses

were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code

and all files used in this analysis is available at GitHub

(https://github.com/MGormley12/metabolic_trait_hnc_mr.git).

Competing interests

The authors declare that they have no competing interests

Funding

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is

currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].

For the purpose of open access, the author has applied a CC BY public copyright licence to

any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC

research fellow at the University of Bristol. J.T. is supported by an Academy of Medical

Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,

Global Challenges Research Fund (GCRF), the Government Department of Business, Energy

and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N.

was supported by the National Institute for Health Research (NIHR) Bristol Biomedical

Research Centre which is funded by the National Institute for Health Research (NIHR) and is

a partnership between University Hospitals Bristol NHS Foundation Trust and the University

of Bristol. Department of Health and Social Care disclaimer: The views expressed are those

of the authors and not necessarily those of the NHS, the NIHR or the Department of Health

and Social Care. This publication presents data from the Head and Neck 5000 which

contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The

Head and Neck 5000 study was a component of independent research funded by the

National Institute for Health Research (NIHR) under its Programme Grants for Applied

Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of

the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Core funding was also provided through awards from Above and Beyond, University

Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator

award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research

UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919).

The VOYAGER study was supported in part by the US National Institute of Dental and

Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and

controls was performed at the Center for Inherited Disease Research (CIDR) and funded by

the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0).

E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are

supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer

Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V.,

R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at

the University of Bristol supported by the Medical Research Council (MC_UU_00011/1,

MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).

718   Authors' contributions

M.G., E.E.V., R.C.R. and C.B. conceived the study and M.G. carried out data curation and

analysis. Head and neck cancer summary genetic data was obtained through multiple

collaborations from studies lead by A.R.N., S.J.T., and M.P. as well as members of VOYAGER

and HEADSpAcE consortia. The initial manuscript was drafted by M.G., E.E.V. and C.B..

Expert guidance on MR methodology was provided by T.D., C.B. and G.D.S. All authors M.G.,

T.D., S.J.T., J.T., A.R.N., M.P., D.L., G.D.S., R.C.R., E.E.V., and C.B. contributed to the

interpretation of the results and critical revision of the manuscript. All authors read and

approved the final manuscript. M.G. supervisory team includes R.C.R., E.E.V., J.T., A.R.N and

G.D.S.